← Eichor
Study identifier: NCT07009691 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

Condition: Chronic Fatigue Syndrome  ·  Sponsor: Stony Brook University

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are: Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS? Can HRV be used to predict who will benefit from treatment with hydrogen water?

This description comes directly from the study's public registry record.

Talk to the study team

Fred Friedberg, PhD  ·  15167024213  ·  fred.friedberg@stonybrookmedicine.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stony Brook UniversityStony Brook, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07009691